Methylation of the RIN3 Promoter is Associated with Transient Ischemic Stroke/Mild Ischemic Stroke with Early Cognitive Impairment [Corrigendum]

Miao M, Yuan F, Ma X, et al. *Neuropsychiatr Dis Treat*. 2021;17:2587–2598. The authors apologize for this error.

The authors have advised that Table 1 and Table 2 are incorrect. The correct tables are shown below.

Table 1 Clinical Information on the Transient Ischemic Stroke/Mild Ischemic Stroke and Control Groups

	TIA/MIS Group (n=84)	Control Group (n=28)	P value
Age (years) ($\bar{x} \pm s$)	61.94 $\pm$ 8.08	57.64 $\pm$ 9.16	0.016
Females (n [%])	26 (31.0)	15 (53.6)	0.054
Education (years)			0.004
≤ 6	22	1	
≤ 12	51	19	
> 12	11	8	
Diabetes mellitus (n [%])	34 (40.5)	9 (32.1)	0.575
Hypertension (n [%])	63 (75.0)	19 (67.9)	0.622
Hyperlipemia (n [%])	22 (26.2)	14 (50.0)	0.035
Coronary heart disease (n [%])	16 (19.0)	8 (28.6)	0.425
Alcohol (n [%])	33 (39.3)	6 (21.4)	0.137
Smoking (n [%])	35 (41.7)	9 (32.1)	0.503
Abnormal scale			
BNT (n [%])	16 (19.0)		
AVLT (n [%])	43 (51.2)		
TMT-A (n [%])	39 (46.4)		
TMT-B (n [%])	38 (45.2)		
Fazekas PV			<0.001
0 (n [%])	1 (1.2)	10 (35.7)	
1 (n [%])	43 (51.2)	17 (60.7)	
2 (n [%])	27 (32.1)	1 (3.6)	
3 (n [%])	13 (15.5)	0 (0)	
Fazekas DWM			<0.001
0 (n [%])	7 (8.3)	12 (42.9)	
1 (n [%])	44 (52.4)	14 (50.00)	
2 (n [%])	26 (31.00)	2 (7.1)	
3 (n [%])	7 (8.3)	0 (0)	
LDL (mmol/L)	2.81 $\pm$ 1.01	3.12 $\pm$ 1.04	0.088

(Continued)

Table 1 (Continued).

	TIA/MIS Group (n=84)	Control Group (n=28)	P value
HDL (mmol/L)	1.08 ± 0.24	1.20 ± 0.31	0.074
HCY (μmol/L)	13.55 ± 7.24	12.45 ± 6.13	0.247
UA (μmol/L)	323.37 ± 84.69	339.37 ± 99.45	0.457
Vitamin B12 (pg/mL)	403.83 ± 253.60	467.30 ± 196.29	0.057

Notes: In the TIA/MIS group, 81 patients underwent low-density lipoprotein (LDL) testing, 80 underwent high-density lipoprotein (HDL) testing, 75 underwent homocysteine (HCY) testing, 82 underwent uric acid (UA) testing, and 63 underwent vitamin B12 testing. In the control group, 27 participants underwent LDL and HDL testing, 25 underwent HCY testing, 27 underwent UA testing, and 20 underwent vitamin B12 testing.

Abbreviations: PV, periventricular; DWM, deep white matter.

Table 2 Clinical Information on the Cognitive-Impairment and Non-Cognitive-Impairment Groups

	Cognitive Impairment Group (n=55)	Non-Cognitive Impairment Group (n=29)	P value
Age (years) ($\bar{x} \pm s$)	63.47 ± 6.95	59.03 ± 9.32	0.029
female (n [%])	20 (36.4)	6 (20.7)	0.219
Education (years)			0.001
≤ 6	20	2	
≤ 12	31	20	
> 12	4	7	
Diabetes mellitus (n [%])	21 (38.2)	13 (44.8)	0.722
Hypertension (n [%])	38 (69.1)	25 (86.2)	0.145
Hyperlipemia (n [%])	14 (25.5)	8 (27.6)	1
Coronary heart disease (n [%])	14 (25.5)	2 (6.9)	0.077
TOAST			0.077
Large artery atherosclerosis (n [%])	26 (47.3)	7 (24.1)	
Small artery occlusion (n [%])	29 (52.7)	22 (75.9)	
Alcohol (n [%])	22 (40.0)	11 (37.9)	1
Smoking (n [%])	24 (43.6)	11 (37.9)	0.786
Abnormal scale			
BNT (n [%])	16 (29.1)		
AVLT (n [%])	43 (78.2)		
TMT-A (n [%])	39 (70.9)		
TMT-B (n [%])	38 (69.1)		
NIHSS			0.935
0 (n [%])	26 (47.3)	14 (48.3)	
1 (n [%])	14 (25.5)	7 (24.1)	
2 (n [%])	10 (18.2)	5 (17.2)	
3 (n [%])	4 (7.3)	2 (6.9)	
4 (n [%])	1 (1.8)	1 (3.4)	

(Continued)

Table 2 (Continued).

	Cognitive Impairment Group (n=55)	Non-Cognitive Impairment Group (n=29)	P value
Fazekas PV			0.661
0 (n [%])	1 (1.8)	0 (0)	
1 (n [%])	26 (47.3)	17 (58.6)	
2 (n [%])	19 (34.5)	8 (27.6)	
3 (n [%])	9 (16.4)	4 (13.8)	
Fazekas DWM			0.063
0 (n [%])	3 (5.5)	4 (13.8)	
1 (n [%])	26 (47.3)	18 (62.1)	
2 (n [%])	20 (36.4)	6 (20.7)	
3 (n [%])	6 (10.9)	1 (3.4)	
LDL (mmol/L)	2.78 ± 1.09	2.87 ± 0.84	0.483
HDL (mmol/L)	1.10 ± 0.24	1.05 ± 0.26	0.189
HCY (μmol/L)	14.15 ± 8.00	12.35 ± 5.37	0.320
UA (μmol/L)	310.93 ± 79.27	347.36 ± 90.98	0.079
Vitamin B12 (pg/mL)	411.61 ± 266.67	389.32 ± 232.57	0.784

Notes: In the cognitive-impairment group, 54 patients underwent low-density lipoprotein (LDL) testing, 53 patients underwent high-density lipoprotein (HDL) testing, 50 underwent homocysteine (HCY) testing, 54 underwent uric acid (UA) testing, and 41 underwent vitamin B12 testing. In the non-cognitive-impairment group, 27 patients underwent LDL and HDL testing, 25 underwent HCY testing, 28 underwent UA testing, and 22 underwent vitamin B12 testing.

Abbreviations: PV, periventricular; DWM, deep white matter; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in acute stroke treatment.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and

is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>